{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:08:33Z","timestamp":1785017313561,"version":"3.55.0"},"reference-count":263,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.pharmr.2025.100037","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T19:02:36Z","timestamp":1736276556000},"page":"100037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulants: From chance discovery to structure-based design"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-6172","authenticated-orcid":false,"given":"Noel","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-919X","authenticated-orcid":false,"given":"Stephanie","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmr.2025.100037_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365516809076981","article-title":"Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis","volume":"21","author":"Abildgaard","year":"1968","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.pharmr.2025.100037_bib2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.14309\/ajg.0000000000001627","article-title":"American College of Gastroenterology-Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period","volume":"117","author":"Abraham","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmr.2025.100037_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"Amadeus Investigators","year":"2008","journal-title":"Lancet"},{"issue":"4 Suppl S","key":"10.1016\/j.pharmr.2025.100037_bib6","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S0735-1097(02)02776-6","article-title":"Oral anticoagulants in patients with coronary artery disease","volume":"41","author":"Anand","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib7","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.pharmr.2025.100037_bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmr.2025.100037_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib11","doi-asserted-by":"crossref","first-page":"43809","DOI":"10.1074\/jbc.M105294200","article-title":"Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding\u2217","volume":"276","author":"Arocas","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100037_bib12","doi-asserted-by":"crossref","first-page":"38462","DOI":"10.1074\/jbc.M205902200","article-title":"The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation","volume":"277","author":"Baird","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100037_bib13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"Barritt","year":"1960","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A\u00a0prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1527-3466.2002.tb00081.x","article-title":"Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents \u2014 the selective factor Xa inhibitors","volume":"20","author":"Bauer","year":"2002","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.pharmr.2025.100037_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/01.CIR.19.1.79","article-title":"Preparation of heparin and its use in the first clinical cases","volume":"19","author":"Best","year":"1959","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0006-3002(56)90393-6","article-title":"The clotting of fibrinogen. II. Fractionation of peptide material liberated","volume":"19","author":"Bettelheim","year":"1956","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmr.2025.100037_bib18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","article-title":"Bivalirudin versus heparin during PCI in NSTEMI: individual patient data meta-analysis of large randomized trials","volume":"148","author":"Bikdeli","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib19","first-page":"411","article-title":"Structure of fibrinopeptides, its relation to enzyme specificity and phylogeny and classification of species","volume":"25","author":"Blomb\u00e4ck","year":"1966","journal-title":"Ark Kemi"},{"key":"10.1016\/j.pharmr.2025.100037_bib20","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.bja.2018.01.023","article-title":"Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review","volume":"120","author":"Boer","year":"2018","journal-title":"British J Anaesth"},{"key":"10.1016\/j.pharmr.2025.100037_bib21","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/00016348809004178","article-title":"Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery","volume":"67","author":"Borstad","year":"1988","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.pharmr.2025.100037_bib23","first-page":"19","article-title":"Oral anticoagulant drugs: pharmacokinetic aspects","volume":"15","author":"Breckenridge","year":"1978","journal-title":"Semin Hematol"},{"key":"10.1016\/j.pharmr.2025.100037_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1152\/ajplegacy.1939.125.4.683","article-title":"The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin","volume":"125","author":"Brinkhous","year":"1939","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib25","first-page":"3788","article-title":"Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Buckley","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"B\u00fcller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib27","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejim.2023.04.024","article-title":"Routine measurement of DOAC concentrations for prognostication and clinical management in acute ischemic stroke: is it ready for prime time?","volume":"113","author":"Carlin","year":"2023","journal-title":"Eur J Int Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib29","first-page":"659","article-title":"The heparin-protamine interaction: a review","volume":"40","author":"Carr","year":"1999","journal-title":"J\u00a0Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.pharmr.2025.100037_bib30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib31","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.V59.6.1239.1239","article-title":"The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits","volume":"59","author":"Carter","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj1970599","article-title":"The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies","volume":"197","author":"Casu","year":"1981","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmr.2025.100037_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1160\/TH16-04-0266","article-title":"Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis","volume":"116","author":"Chai-Adisaksopha","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib34","first-page":"16","article-title":"Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic","volume":"14","author":"Chamberlain","year":"2001","journal-title":"J\u00a0Am Board Fam Pract"},{"key":"10.1016\/j.pharmr.2025.100037_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14779072.2023.2271388","article-title":"Unresolved issues in the use of direct acting oral anticoagulants","volume":"21","author":"Chan","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.pharmr.2025.100037_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2017.10.002","article-title":"Is there a role for pharmacokinetic\/pharmacodynamic-guided dosing for novel oral anticoagulants?","volume":"199","author":"Chan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmr.2025.100037_bib37","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib38","first-page":"343","article-title":"Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism","volume":"11","author":"Chan","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.pharmr.2025.100037_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/jth.12823","article-title":"Real-world variability in dabigatran levels in patients with atrial fibrillation","volume":"13","author":"Chan","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib40","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1365-2168.2000.01352.x","article-title":"Warfarin induced skin necrosis","volume":"87","author":"Chan","year":"2002","journal-title":"Br J Surg"},{"key":"10.1016\/j.pharmr.2025.100037_bib42","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-07-368811","article-title":"Polyphosphate is a cofactor for the activation of factor XI by thrombin","volume":"118","author":"Choi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib43","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib44","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJM198805053181805","article-title":"Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery","volume":"318","author":"Collins","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib46","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib47","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease\u2013associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib48","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute itracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib49","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCRESAHA.112.264903","article-title":"Translational success stories: development of direct thrombin inhibitors","volume":"111","author":"Coppens","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmr.2025.100037_bib51","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A\u00a0comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.ATV.0000168421.13467.82","article-title":"Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition","volume":"25","author":"Dahlb\u00e4ck","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.303.6796.224","article-title":"Prevention of venous thrombosis with minidose warfarin after joint replacement","volume":"303","author":"Dale","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.pharmr.2025.100037_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1440-1797.2009.01135.x","article-title":"Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments","volume":"14","author":"Davenport","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.pharmr.2025.100037_bib55","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1126\/science.145.3638.1310","article-title":"Waterfall sequence for intrinsic blood clotting","volume":"145","author":"Davie","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.pharmr.2025.100037_bib56","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1055\/s-0041-1740492","article-title":"Can a single measurement of Apixaban levels identify patients at risk of overexposure? A prospective cohort study","volume":"6","author":"de Vries","year":"2022","journal-title":"TH Open"},{"key":"10.1016\/j.pharmr.2025.100037_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.122.008982","article-title":"Letter by de Vries et\u00a0al regarding article \u201cOff-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis\u201d","volume":"15","author":"de Vries","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pharmr.2025.100037_bib58","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1055\/s-0040-1713889","article-title":"Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?\u2014A systematic review","volume":"120","author":"de Vries","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib59","article-title":"Usual on-therapy ranges of drug concentrations in patients with atrial fibrillation treated with direct oral anticoagulants: a systematic review and meta-analysis","author":"de Vries","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1538-7836.2007.02485.x","article-title":"Thrombin as procoagulant and anticoagulant","volume":"5","author":"Di Cera","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mam.2008.01.001","article-title":"Thrombin","volume":"29","author":"Di Cera","year":"2008","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib62","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/archinte.168.16.1805","article-title":"Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study","volume":"168","author":"Douketis","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib63","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib64","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib65","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib66","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.jtha.2023.06.036","article-title":"Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials","volume":"21","author":"Eikelboom","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib67","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib68","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib69","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1172\/JCI116404","article-title":"Importance of factor Xa in determining the procoagulant activity of whole-blood clots","volume":"91","author":"Eisenberg","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100037_bib70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrd2622","article-title":"Dabigatran etexilate","volume":"7","author":"Eriksson","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmr.2025.100037_bib71","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM199711063371901","article-title":"A\u00a0comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement","volume":"337","author":"Eriksson","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib72","series-title":"Advances in Protein Chemistry","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3233(08)60307-1","article-title":"Protamines","author":"Felix","year":"1961"},{"key":"10.1016\/j.pharmr.2025.100037_bib73","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib74","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A\u00a0randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib75","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.303.6796.219","article-title":"Efficacy of fixed minidose warfarin prophylaxis in total hip replacement","volume":"303","author":"Fordyce","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.pharmr.2025.100037_bib76","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in\u00a0vitro and in\u00a0vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000371449","article-title":"Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease","volume":"129","author":"Galloway","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.pharmr.2025.100037_bib78","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(86)91431-5","article-title":"Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism","volume":"2","author":"Gallus","year":"1986","journal-title":"Lancet"},{"issue":"2 Suppl","key":"10.1016\/j.pharmr.2025.100037_bib79","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"6 Suppl","key":"10.1016\/j.pharmr.2025.100037_bib80","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.pharmr.2025.100037_bib81","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib82","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A\u00a0comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes","volume":"335","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib83","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","article-title":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial","volume":"385","author":"Goldstein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib84","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e3675","article-title":"Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons","volume":"344","author":"G\u00f3mez-Outes","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.pharmr.2025.100037_bib86","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib87","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.pharmr.2025.100037_bib88","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V96.3.846","article-title":"Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range","volume":"96","author":"Greinacher","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.878199","article-title":"Anticoagulant SERPINs: endogenous regulators of hemostasis and thrombosis","volume":"9","author":"Grover","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib90","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.293.6.736","article-title":"Ximelagatran\u2014promises and concerns","volume":"293","author":"Gurewich","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100037_bib91","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2005-916161","article-title":"Discovery of ximelagatran in an historical perspective","volume":"5","author":"Gustafsson","year":"2005","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib92","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0037-1614245","article-title":"Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes","volume":"79","author":"Gustafsson","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib93","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd1466","article-title":"A\u00a0new oral anticoagulant: the 50-year challenge","volume":"3","author":"Gustafsson","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmr.2025.100037_bib94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00280041","article-title":"Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin","volume":"39","author":"Handeland","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100037_bib96","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1160\/TH09-08-0555","article-title":"Development of idraparinux and idrabiotaparinux for anticoagulant therapy","volume":"102","author":"Harenberg","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib97","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib98","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1098\/rspl.1883.0135","article-title":"IV. On the action of a secretion obtained from the medi-cinal leech on the coagulation of the blood","volume":"36","author":"Haycraft","year":"1883","journal-title":"Proc R Soc Lond"},{"key":"10.1016\/j.pharmr.2025.100037_bib99","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jtha.2022.11.014","volume":"21","author":"Helms","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib100","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib101","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1161\/01.CIR.98.15.1575","article-title":"Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina","volume":"98","author":"Hirsh","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib102","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1160\/th14-05-0433","article-title":"Solving the mystery of excessive warfarin-induced bleeding: a personal historical perspective","volume":"112","author":"Hirsh","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib103","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib104","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"issue":"6 Suppl","key":"10.1016\/j.pharmr.2025.100037_bib105","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.pharmr.2025.100037_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.10.023","article-title":"Fifty years of research on antithrombotic therapy: achievements and disappointments","volume":"70","author":"Hirsh","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib107","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100037_bib108","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A\u00a0cell-based model of coagulation and the role of factor VIIa","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.pharmr.2025.100037_bib109","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1073\/pnas.86.10.3619","article-title":"Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy","volume":"86","author":"Hogg","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100037_bib110","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"HOKUSAI-VTE-Investigators","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib111","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pharmr.2025.100037_bib112","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.pharmr.2025.100037_bib113","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1152\/ajplegacy.1918.47.3.328","article-title":"Two new factors in blood coagulation\u2014heparin and pro-antithrombin","volume":"47","author":"Howell","year":"1918","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib114","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.3390\/ijms22084200","article-title":"VWF, platelets and the antiphospholipid syndrome","volume":"22","author":"Huang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100037_bib115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM198201283060401","article-title":"Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis","volume":"306","author":"Hull","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib116","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJM197910183011602","article-title":"Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis","volume":"301","author":"Hull","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib117","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198212303072704","article-title":"Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis","volume":"307","author":"Hull","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib118","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis","volume":"315","author":"Hull","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib119","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199005033221802","article-title":"Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis","volume":"322","author":"Hull","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100037_bib120","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib121","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.pharmr.2025.100037_bib122","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.V75.2.399.bloodjournal752399","article-title":"Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin","volume":"75","author":"Jakubowski","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib123","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1073\/pnas.94.26.14683","article-title":"The anticoagulant activation of antithrombin by heparin","volume":"94","author":"Jin","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100037_bib124","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib125","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib126","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1016\/S0021-9258(19)70431-1","article-title":"The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin","volume":"255","author":"Jordan","year":"1980","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100037_bib127","first-page":"45","article-title":"Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial","volume":"2","author":"Kakkar","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1538-7836.2004.01031.x","article-title":"Low-dose heparin to low molecular weight heparin prophylaxis: in pursuit of excellence \u2013 a personal perspective","volume":"3","author":"Kakkar","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib129","first-page":"567","article-title":"Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial","volume":"1","author":"Kakkar","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.10079","article-title":"Availability of specific direct oral anticoagulant reversal agents in US hospitals","volume":"4","author":"Kanjee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pharmr.2025.100037_bib131","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.296.8.935","article-title":"Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism","volume":"296","author":"Kearon","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100037_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197904010-00001","article-title":"Clinical pharmacokinetics of oral anticoagulants","volume":"4","author":"Kelly","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmr.2025.100037_bib133","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pharmr.2025.100037_bib134","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib135","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib136","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group","volume":"334","author":"Koopman","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib137","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/oxfordjournals.eurheartj.a060499","article-title":"Activation and destruction of platelets in patients with rheumatic heart disease","volume":"15","author":"Kunishima","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmr.2025.100037_bib138","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100037_bib139","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A\u00a0comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis","volume":"334","author":"Levine","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib141","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib142","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nsmb811","article-title":"Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin","volume":"11","author":"Li","year":"2004","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib143","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1097\/01.ASN.0000145014.80714.35","article-title":"Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials","volume":"15","author":"Lim","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.pharmr.2025.100037_bib144","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.V128.22.90.90","article-title":"Serial trough anti-Xa levels to assess low molecular weight heparin accumulation in patients with chronic kidney disease: analysis of Crcl <30 ml\/min from the Trivet study","volume":"128","author":"Lim","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib145","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1073\/pnas.76.7.3198","article-title":"Structure of the antithrombin-binding site in heparin","volume":"76","author":"Lindahl","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100037_bib146","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/01.CIR.19.1.97","article-title":"The discovery of dicumarol and its sequels","volume":"19","author":"Link","year":"1959","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib147","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/rth2.12145","article-title":"Systematic review of fondaparinux for heparin-induced thrombocytopenia: when there are no randomized controlled trials","volume":"2","author":"Linkins","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib148","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.pharmr.2025.100037_bib149","first-page":"634","article-title":"Interaction of andexanet\u00a0alfa, a universal antidote to fXA inhibitors, with tissue factor pathway inhibitor enhances reversal of fXA inhibitor-induced anticoagulation","volume":"13","author":"Lu","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib150","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/j.1538-7836.2005.01623.x","article-title":"Lepirudin in patients with heparin-induced thrombocytopenia\u2013results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3","volume":"3","author":"Lubenow","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib151","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.163.20.2469","article-title":"Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study","volume":"163","author":"Lubetsky","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib152","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12967-022-03859-w","article-title":"Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial","volume":"21","author":"Ma","year":"2023","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib153","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100037_bib154","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin","volume":"29","author":"Maraganore","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmr.2025.100037_bib155","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/jhmas\/52.3.310","article-title":"The development of heparin in Toronto","volume":"52","author":"Marcum","year":"1997","journal-title":"J\u00a0Hist Med Allied Sci"},{"key":"10.1016\/j.pharmr.2025.100037_bib156","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00245864","article-title":"[Studies on the mechanism of the anticoagulant effect of hirudin]","volume":"229","author":"Markwardt","year":"1956","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"key":"10.1016\/j.pharmr.2025.100037_bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-3848(94)90032-9","article-title":"The development of hirudin as an antithrombotic drug","volume":"74","author":"Markwardt","year":"1994","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib158","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/107602969600200201","article-title":"State-of-the-art review: antithrombotic agents from hematophagous animals","volume":"2","author":"Markwardt","year":"1996","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib159","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-2002-35292","article-title":"Hirudin as alternative anticoagulant- a historical review","volume":"28","author":"Markwardt","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib160","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib161","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjmed.2016.12.033","article-title":"Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance","volume":"130","author":"Martin","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib162","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib163","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1161\/01.CIR.19.1.75","article-title":"The discovery of heparin","volume":"19","author":"Mclean","year":"1959","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib164","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib165","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/hae.14356","article-title":"Natural anticoagulants: a missing link in mild to moderate bleeding tendencies","volume":"27","author":"Mehic","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.pharmr.2025.100037_bib166","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/jcem-64-1-59","article-title":"Impaired carboxylation of osteocalcin in warfarin-treated patients","volume":"64","author":"Menon","year":"1987","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100037_bib167","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet\u00a0alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib168","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/01.CIR.72.5.1059","article-title":"Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial","volume":"72","author":"Mok","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib169","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/01.RES.3.4.397","article-title":"Studies on the antithrombin and heparin cofactor activities of a fraction adsorbed from plasma by aluminum hydroxide","volume":"3","author":"Monkhouse","year":"1955","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112878","article-title":"From ancient leech to direct thrombin inhibitors and beyond: new from old","volume":"149","author":"Montinari","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100037_bib171","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/01.CIR.89.1.432","article-title":"History of drugs for thrombotic disease. Discovery, development, and directions for the future","volume":"89","author":"Mueller","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib172","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib174","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-291X(81)91279-1","article-title":"Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion","volume":"101","author":"Okamoto","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmr.2025.100037_bib175","first-page":"43","article-title":"A\u00a0novel series of synthetic thrombin-inhibitors having extremely potent and highly selective action","volume":"21","author":"Okamoto","year":"1975","journal-title":"Kobe J Med Sci"},{"key":"10.1016\/j.pharmr.2025.100037_bib176","series-title":"Vitamins & Hormones","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0083-6729(07)00003-9","article-title":"The vitamin K cycle","volume":"vol 78","author":"Oldenburg","year":"2008"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100037_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1538-7836.2007.02549.x","article-title":"VKORC1: molecular target of coumarins","volume":"5","author":"Oldenburg","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib178","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100037_bib179","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.ATV.19.1.170","article-title":"Thrombin activates factor XI on activated platelets in the absence of factor XII","volume":"19","author":"Oliver","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.me.27.020176.001333","article-title":"Vitamin K and the oral anticoagulant drugs","volume":"27","author":"O'Reilly","year":"1976","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib181","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","article-title":"Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib182","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pharmr.2025.100037_bib183","first-page":"e35","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib184","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1160\/TH09-11-0771","article-title":"Tissue factor and thrombosis: the clot starts here","volume":"104","author":"Owens","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib185","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/eurheartj\/ehaa194","article-title":"Carl Peter Henrik Dam and Edward Adelbert Doisy","volume":"41","author":"Ozkan","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmr.2025.100037_bib186","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib187","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.123.066279","article-title":"Efficacy and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and body weight: an individual patient data meta-analysis of 4 randomized clinical trials of patients with atrial fibrillation","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib188","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmr.2025.100037_bib189","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1021\/jm960726z","article-title":"Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A\/ORG 31540)","volume":"40","author":"Petitou","year":"1997","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.pharmr.2025.100037_bib190","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib191","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2014 full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100037_bib263","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib192","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib193","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(67)91109-9","article-title":"A\u00a0national standard for anticoagulant therapy: the Manchester comparative reagent","volume":"289","author":"Poller","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib194","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1538-7836.2004.00775.x","article-title":"International normalized ratios (INR): the first 20 years","volume":"2","author":"Poller","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2141.1982.00479.x","article-title":"Dosage and control of oral anticoagulants: an international collaborative survey","volume":"51","author":"Poller","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmr.2025.100037_bib196","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/antiox10040566","article-title":"The role of vitamin K in humans: implication in aging and age-associated diseases","volume":"10","author":"Popa","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.pharmr.2025.100037_bib197","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.164.10.1077","article-title":"Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism","volume":"164","author":"Prandoni","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib198","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa1014475","article-title":"Dalteparin versus unfractionated heparin in critically ill patients","volume":"364","author":"PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.pharmr.2025.100037_bib199","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(16)30354-1","article-title":"The hemostatic role of factor XI","volume":"141","author":"Puy","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib200","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1357-2725(03)00244-9","article-title":"Antithrombin: in control of coagulation","volume":"36","author":"Quinsey","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib201","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S2352-3026(16)00023-5","article-title":"Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.pharmr.2025.100037_bib202","doi-asserted-by":"crossref","first-page":"C365","DOI":"10.1152\/ajpcell.00056.2020","article-title":"Role of platelets in regulating activated coagulation factor XI activity","volume":"320","author":"Reitsma","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib203","series-title":"Hemostasis and Thrombosis, Basic Principles and Clinical Practice","first-page":"837","article-title":"The heparin-antithrombin system: a natural anticoagulant mechanism","author":"Rosenberg","year":"1994"},{"key":"10.1016\/j.pharmr.2025.100037_bib204","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1016\/S0021-9258(19)43472-8","article-title":"The purification and mechanism of action of human antithrombin-heparin cofactor","volume":"248","author":"Rosenberg","year":"1973","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100037_bib205","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib206","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1126\/science.2374926","article-title":"The structure of a complex of recombinant hirudin and human \u03b1-thrombin","volume":"249","author":"Rydel","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.pharmr.2025.100037_bib207","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib208","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00216-010-4220-8","article-title":"Protamine neutralisation of low molecular weight heparins and their oligosaccharide components","volume":"399","author":"Schroeder","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.pharmr.2025.100037_bib209","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100037_bib210","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib211","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib212","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.pharmr.2025.100037_bib213","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","article-title":"A\u00a0comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty","volume":"333","author":"Serruys","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib214","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmr.2025.100037_bib215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-nutr-082117-051741","article-title":"Key pathways and regulators of vitamin K function and intermediary metabolism","volume":"38","author":"Shearer","year":"2018","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.pharmr.2025.100037_bib216","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib217","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1055\/s-0040-1721734","article-title":"Plasma rivaroxaban level to identify patients at risk of drug overexposure: is a single measurement of drug level reliable?","volume":"5","author":"Shyamkumar","year":"2021","journal-title":"TH Open"},{"key":"10.1016\/j.pharmr.2025.100037_bib218","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet\u00a0alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib219","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1538-7836.2011.04458.x","article-title":"No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy","volume":"9","author":"Siguret","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078972","article-title":"Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100037_bib221","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archinte.164.1.66","article-title":"Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia","volume":"164","author":"Srinivasan","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib222","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.pharmr.2025.100037_bib223","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmr.2025.100037_bib224","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1096\/fasebj.7.5.8462786","article-title":"Synthesis of vitamin K-dependent proteins","volume":"7","author":"Suttie","year":"1993","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmr.2025.100037_bib225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.thromres.2021.10.010","article-title":"Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis","volume":"208","author":"Swayngim","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib226","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib227","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib228","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/jth.13217","article-title":"Structural and functional insights into enzymes of the vitamin K cycle","volume":"14","author":"Tie","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib229","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"70","author":"Tomaselli","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100037_bib230","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib231","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0140-6736(88)92070-3","article-title":"Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement","volume":"1","author":"Turpie","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib232","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM198610093151503","article-title":"A\u00a0randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery","volume":"315","author":"Turpie","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib233","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmr.2025.100037_bib234","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib235","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100037_bib236","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/jth.14156","article-title":"Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Vasanthamohan","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib237","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1160\/TH15-04-0336","article-title":"Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway","volume":"115","author":"Vu","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib238","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib239","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.pharmr.2025.100037_bib240","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","article-title":"The story of the discovery of heparin and warfarin","volume":"141","author":"Wardrop","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmr.2025.100037_bib241","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/14740338.2013.823946","article-title":"Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls","volume":"13","author":"Warkentin","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharmr.2025.100037_bib242","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0044-1786356","article-title":"Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review","volume":"50","author":"Warkentin","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib243","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib244","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/ATVBAHA.118.310960","article-title":"Advances in antithrombotic therapy","volume":"39","author":"Weitz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib246","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.2019000919","article-title":"Novel antithrombotic strategies for treatment of venous thromboembolism","volume":"135","author":"Weitz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib247","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100037_bib248","first-page":"3","article-title":"Vitamin K-dependent proteins involved in bone and cardiovascular health","volume":"18","author":"Wen","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharmr.2025.100037_bib249","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib250","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0267659120952982","article-title":"Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"36","author":"Willems","year":"2021","journal-title":"Perfusion"},{"key":"10.1016\/j.pharmr.2025.100037_bib251","first-page":"293","article-title":"Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial","volume":"169","author":"Wilson","year":"2003","journal-title":"CMAJ"},{"key":"10.1016\/j.pharmr.2025.100037_bib252","first-page":"478","article-title":"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor","volume":"31","author":"Wong","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100037_bib253","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(54)90838-7","article-title":"Myocardial infarction and its treatment with anticoagulants; summary of findings in 1031 cases","volume":"266","author":"Wright","year":"1954","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100037_bib254","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in\u00a0vitro and in\u00a0vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2025.100037_bib255","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","article-title":"Oral direct factor Xa inhibitors","volume":"111","author":"Yeh","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmr.2025.100037_bib256","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/01.ATV.17.8.1568","article-title":"Induction of the acute-phase reaction increases heparin-binding proteins in plasma","volume":"17","author":"Young","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100037_bib257","article-title":"Quantitative benefit\u2013risk evaluation of rivaroxaban in patients after peripheral arterial revascularization: the VOYAGER PAD trial","volume":"13","author":"Yuan","year":"2024","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.pharmr.2025.100037_bib258","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl) benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharmr.2025.100037_bib259","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.007971","article-title":"Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis","volume":"14","author":"Zhang","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pharmr.2025.100037_bib260","doi-asserted-by":"crossref","first-page":"26139","DOI":"10.1074\/jbc.272.42.26139","article-title":"The mechanism by which heparin promotes the inhibition of coagulation factor XIa by protease nexin-2","volume":"272","author":"Zhang","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100037_bib261","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/HYPERTENSIONAHA.115.06254","article-title":"Growth arrest\u2013specific 6 exacerbates pressure overload\u2013induced cardiac hypertrophy","volume":"67","author":"Zhao","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmr.2025.100037_bib262","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","article-title":"Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"9","author":"Zimerman","year":"2024","journal-title":"JAMA Cardiol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:47:47Z","timestamp":1762217267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":263,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0031699725000018"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100037","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulants: From chance discovery to structure-based design","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100037"}}